Corin's Optimized Positioning System (OPS™) receives 510(k) clearance

7 June 2016 

Corin is pleased to announce United States 510(k) clearance of the Optimized Positioning System (OPS™), the first FDA-cleared technology to help surgeons achieve functional, patient specific component alignment in total hip replacement.

The approval allows Corin to be the first company to offer a technology that optimises the orientation of each individual patient's acetabular component by incorporating functional assessments into the planning phase, whilst utilising a laser guided Patient Specific Instrument platform to accurately reproduce the surgical plan intra-operatively.

Following the acquisition of the technology in 2014 a significant number of procedures in Australia and Europe have been completed, Corin now look forward to launching OPS™ in the world's largest orthopaedic market. The combination of the IP-protected OPS™ technology, alongside the company's strong hip portfolio and rapidly expanding distribution network, provide a strong foundation for future growth of the company.

Jim Pierrepont, Corin's Head of Procedural Technologies commented 'œWe are delighted to gain access to the US market and be the first company to offer such an exciting technology. This solution is a significant step forward in helping to improve the performance of total hip replacement, as conventional acetabular cup placement does not take into account the patient's individual functional movement and relies instead on guidance for cup positioning defined some 36 years ago'.

Pierrepont went on to say 'œBy commercialising the OPS™ technology, Corin will offer surgeons and patients a unique customised, patient specific solution for hip surgery that will help to provide optimal implant positioning with the goal of improved functional outcome'

Corin's US President, Paul Berman added, 'OPS™ is the first orthopaedic technology to facilitate functional implant positioning without adding complexity or substantial cost to the surgical procedure.  We are excited to be bringing this technology to the US to further advance orthopaedic care.'